Afghanistan is first country to recognise Indian Pharmacopoeia, standards for drugs & medicine

New Delhi: The Indian Pharmacopoeia (IP) has been recognised formally by the National Department of Regulation of Medicines and Health Products of the Ministry of Public Health of Islamic Republic of Afghanistan. It will also be used based on the requirement as reputable pharmacopoeia in the laboratory of medicines and health products quality. With this, Afghanistan has become the first country to recognize IP pursuant to the efforts of Department of Commerce, and Ministry of Health & Family Welfare.

IP is an officially recognized book of standards as per the Drugs and Cosmetics Act, 1940, and Rules 1945 thereunder. The IP specifies the standards of drugs manufactured and marketed in India in terms of their identity, purity, and strength.

In order to ensure the quality of medicinal products, the legal and scientific standards are provided by Indian Pharmacopoeia Commission (IPC) in the form of Indian Pharmacopoeia (IP).

As per the Second Schedule of the Drugs and Cosmetics Act, IP is designated as the official book of standards for drugs imported and/or manufactured for sale, stock or exhibition for sale or distribution in India.

The IP Commission’s mission is to promote public & animal health in India by bringing out authoritative and officially accepted standards for quality of drugs including active pharmaceutical ingredients, excipients, and dosage forms used by health professionals, patients and consumers. This is achieved by developing the standards for medicines and supporting their implementation.

In addition, IPC also develops IP Reference Substances (IPRS) that act as a fingerprint for identification of an article under test and its purity as prescribed in the IP monographs. Standards prescribed in the IP are authoritative in nature and enforced by regulatory authorities for quality control of medicines in India.

The ID Staff

Daily stories by the Indus Dictum Staff

Have some feedback for the author? Click here to comment.